Predictive Oncology Inc. (NASDAQ:POAI) announced the appointment of Dr. Christoph Reinhard to its scientific board to serve alongside other key thought leaders in their fields to guide the company’s scientific initiatives and growth strategy.
Dr Reinhard is a leader in oncology translational research, new technologies in drug development, and external innovation, the company said in a statement.
In his role as acting chief scientific officer for CELLphenomics GmbH, he plays an instrumental role in determining what types of novel drugs and drug combinations might be beneficial to future cancer patients with solid tumors, it added.
Dr Reinhard worked at Eli Lilly for more than a decade where his responsibilities included strategy development and implementation of translational research support for its oncology portfolio assets, and he is the co-founder and director of the Board for Asian Cancer Research Group.
“We are fortunate to have someone on our scientific advisory board with such extensive experience in the biopharmaceutical industry with a deep understanding of oncology and translational science,” said Predictive Oncology CEO Raymond F Vennare.
“Dr. Reinhard’s personal and professional commitment is both impressive and honorable, and his insights into oncology drug development will prove invaluable as we continue to gain momentum with oncology drug development partners around the world.”
Dr Reinhard said he was excited about the opportunities that Predictive Oncology offers in drug discovery and the advancements its scientists have made in partnering with biopharmaceuticals to bring cancer therapies forward.
“Predictive Oncology has a breakthrough technology with their PEDAL platform that can significantly accelerate early drug discovery and positively impact oncology drug development,” he said.
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie